Skip to content
  • English
  • Business
  • Entertainment
  • National
  • Lifestyle
  • Education
Daily News India

Daily News India

Just another WordPress site

  • English
  • Business
  • Entertainment
  • National
  • Lifestyle
  • Education
  • Toggle search form
  • AFCOM to Acquire Four 777-8F Freighter Aircraft from Boeing Business
  • UAE Investors Eye India’s OTT market Entertainment
  • TCS, IEM Kolkata Join Hands to set up AI Centre of Excellence Sports
  • Bombay Durgabari Marks Its 95th Durgautsav with a Vibrant Celebration of Diversity in India Lifestyle
  • Toreto Accelerates into India’s Booming Car Accessories Market with Cutting-Edge Audio and Lighting Solutions Business
  • Jigyasa IAS Institute Launches A New Centre in Mohali Press Release
  • How to Make Your Summer Break Count: A Roadmap for Indian High School Students Aspiring to Study at Top Universities Abroad Lifestyle
  • Platform that celebrates body positivity, as beauty can’t be boxed! Business

Martin & Harris Labs reports robust results in FY21, PAT zooms 139% to Rs 177 Cr

Posted on January 15, 2022 By

New Delhi, January 15: Martin & Harris Laboratories, the pharmaceutical arm of Apeejay Group, has announced its results for the financial year ended on 31 March, 2021.

In the financial year 2020-21, Martin & Harris Laboratories clocked a profit after tax (PAT) of Rs 177 crore, a rise of 138.96% against a net profit of Rs 70 crore in the financial year 2019-20.

In the last seven years, the revenue of the company has grown at a CAGR of 30% and from Rs 67 crore to 336 crore, whereas PAT has surged at a CAGR of 61% to Rs 177 crore.

The total income for the FY 2020-21 includes Rs 138 crore from pharma business and Rs 196 crore from investment business. Earnings per share (EPS) of the company zoomed to 443 in FY21 against an EPS of 180 in FY20.

In FY21, Delite Infrastructure an investment arm of Martin and Harris Laboratory has generated EBIT of 160 Crores on capital of 400 Crores, which is 40% return on capital. And, though period and portfolio is large, if we benchmark this with Warren Buffet’s investment company Berkshire Hathaway, same has generated 20% CAGR return in the last 40 years. This shows that investment arm of Martin and Harris Laboratory is generating handsome return to shareholders.

Martin & Harris Laboratories have a couple of manufacturing facilities in Roorkee (Uttarakhand) and Una (Himachal Pradesh) wherein they manufacture some famous medicines like Drotin Plus, Amclox, Venusmin and Tamsin etc which are having high demand in the market. The company is constantly taking steps to modernize and expand its manufacturing units to meet international standards.

Apeejay Group was established in 1910 by Shri Pyare Lal Ji, which today has an annual turnover of more than Rs 2,500 Cr. From starting its journey in Jalandhar to manufacture steel goods for the domestic agriculture industry, today Apeejay Group has ventured into hotels, real estates, constructions, shipping and pharmaceuticals. Later on the legacy of Shri Pyare Lal was being carried out by his sons Surrendra and Stya. And, accordingly, the group was divided into two parts i.e. Apeejay Surrendra and Apeejay Stya Group.

Today, Apeejay Stya Group manages Martin and Harris Laboratory i.e. Pharma Business along with Apeejay Education Society and the Apeejay Stya Universities. Dr Stya Paul’s legacy of excellence is being carried forward by his daughter and only child, Mrs Sushma Paul Berlia, Chairman of the Apeejay Education Society.

Apeejay Surrendra Group business activities are presently oversee by his son and daughters i.e. Priya, Priti and Karan Paul.

Valuation

In the pre IPO market, the shares of Martin & Harris Laboratories are trading at Rs 2900-3000 apiece. With an average EPS of Rs 270 for the last three years, it commands a price to earnings (P/E) ratio little more than 10.75 to 11.11x.

On a standalone basis, the company’s pharma arm generated a net profit of Rs 40 crore in FY 2020-21 with an average EPS of Rs 102 for the last three years, it is trading at a P/E ratio of 28x. Nifty Pharma index is trading at a P/E ratio of 33x, there is ample upside left in the company.

Business Tags:Business

Post navigation

Previous Post: First-of-its-kind clinic launched in Lucknow to cure PCOD hormonal disorder in women
Next Post: IG Drones partners up with the Government of Gujarat at Pre-Vibrant Gujarat Summit

Related Posts

  • Indong Tea Company Ltd’s Rs. 13 crore public issue on BSE SME platform opens for subscription on February 9 Business
  • Hubble Explorers Wins ‘Best Preschool Curriculum in India’ at the Early Years Educators Summit and Awards 2025 Business
  • Setting new benchmarks for Ayurvedic treatments – ND Care Nirogam Pvt. Ltd Business
  • Akanksha Maker – Charting A Successful Journey In Travel Writing, Journalism And Brand Management Business
  • YAAP Wins Creative & Media Mandate for Parle Candy Culture Business
  • Supreme Power Equipment Limited Continues Winning Momentum with Strong Order Inflows of Rs 56.86 Cr Business

Recent Posts

  • Top Bathroom Tile Brands in India: Wall, Floor and Anti-Skid Options Compared
  • Parul University moves to 401-500 band in Times Higher Education (THE) Interdisciplinary Science Rankings 2027
  • COLORFUL India Strengthens After-Sales Support Through Association with Kaizen Infoserve
  • ORGATEC India 2026 Outlines a Roadmap for Growth Amid a 15% Rise in Commercial Real Estate Investments
  • From Needle and Thread to Virar’s Spotlight: DhaagaDhari’s Handmade Brand Wins Hearts at Virar Flea Market

Recent Comments

  • Unknown on Participants Reap Rewards in Wellman’s 8-Week Digital Campaign: IPL Tickets, Autographed Virat Kohli Merchandise, and More!
  • Global Vysya Business Legends (GVBL) launched in Hyderabad to support and aid businesses of Arya Vysyas in India and abroad Business
  • 15 Startups to Secure fund at Flagship Business Contest event Clarion Call 5.0 by IIM Calcutta Alumni Association along with IIM Calcutta Innovation Park Business
  • Somany Ceramics inaugurates its Arcade in Srinagar Business
  • British Wellness Brings A New Era in Affordable Healthcare Health
  • eYantra Ventures raises Rs. 15 Crore through preferential issue; eyes global expansion Business
  • Top Benefits of Switching to a Digital Zero Balance Savings Account Finance
  • LAPL Automotive Limited Reports H1 FY27 Results Finance
  • Grand Finale of Sanatan Premier League in Indore; MPR Rajasthan Becomes Champion Sports

Copyright © 2026 Daily News India.

Powered by PressBook News WordPress theme